Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 696 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis, Chronic Clear all

Conditions: Hepatitis C, Chronic
Interventions: ISIS 14803, peginterferon alfa, ribavirin; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • Orange, California + 22 more

Conditions: Chronic Hepatitis B
Interventions: ABI-H0731, Placebo, NrtI; Drug
Lead sponsor: Assembly Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Los Angeles, California • Pasadena, California • San Diego, California + 6 more

Conditions: Chronic Kidney Disease
Interventions: HEPLISAV-B, Engerix-B, Placebo; Biological · Other
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Chronic Hepatitis C
Interventions: Daclatasvir, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: Anaheim, California • Cypress, California • New Haven, Connecticut + 4 more

Conditions: Hepatitis C Virus
Interventions: Daclatasvir, Simeprevir, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: San Francisco, California • Indianapolis, Indiana • Lutherville, Maryland + 3 more

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more

Conditions: Treatment of Hepatitis C
Interventions: Ledipasvir/Sofosbuvir FDC; Drug
Lead sponsor: Peter J. Ruane, M.D., Inc.; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hepatitis C Infection
Interventions: Daclatasvir, Placebo, Peginterferon alpha-2a, ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 11
States / cities: Montgomery, Alabama • Aurora, Colorado • New Haven, Connecticut + 7 more

Conditions: Hepatitis C
Interventions: Peginterferon Lambda-1a (BMS-914143); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 17
States / cities: La Jolla, California • New Haven, Connecticut • Orlando, Florida + 12 more

Conditions: Acute On Chronic Hepatitis
Interventions: ELAD plus standard of care treatment, Standard of care; Biological · Other
Lead sponsor: Vital Therapies, Inc.; Industry
Eligibility: 18 Years to 67 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more

Conditions: Hepatitis C
Interventions: Alisporivir, Boceprevir, Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Beverly Hills, California • Baltimore, Maryland

Conditions: Chronic Hepatitis C
Interventions: Sofosbuvir, RBV, PEG; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 55
States / cities: Birmingham, Alabama • Coronado, California • Los Angeles, California + 43 more

Conditions: Hepatitis C
Interventions: Infergen and ribavirin; Drug
Lead sponsor: Kadmon Corporation, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 4
States / cities: Atlanta, Georgia • New Orleans, Louisiana • Harrisburg, North Carolina + 1 more

Conditions: Liver Fibrosis, Hepatic Fibrosis, Liver Cirrhosis, Hepatic Cirrhosis
Interventions: IDN-6556, Placebo; Drug
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 35
States / cities: Coronado, California • La Jolla, California • Loma Linda, California + 24 more

Conditions: Hepatitis B, Chronic
Interventions: JNJ-73763989, Placebo for JNJ-73763989, JNJ-56136379, Placebo for JNJ-56136379, Nucleos(t)ide Analog (NA); Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 8
States / cities: Bakersfield, California • Los Angeles, California • San Clemente, California + 5 more

Conditions: Hepatic Failure, Hepatic Impairment, Chronic Hepatitis C Infection With Hepatic Coma
Interventions: 2.0mg Buprenorphine/0.5mg Naloxone, Promethazine; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Hialeah, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B, Hepatitis C, Diabetes, COPD
Interventions: Multi-analyte Blood Test; Diagnostic Test
Lead sponsor: Helio Genomics; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Timeline: 2019 – 2028
U.S. locations: 7
States / cities: Redondo Beach, California • Coon Rapids, Minnesota • Fridley, Minnesota + 4 more

Conditions: Hepatitis C, Chronic
Interventions: eltrombopag, placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 59
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 49 more

Conditions: Chronic HBV Infection
Interventions: PBGENE-HBV; Biological
Lead sponsor: Precision BioSciences, Inc.; Industry
Eligibility: 19 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2040
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis B, HBV
Interventions: Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 13
States / cities: Phoenix, Arizona • Costa Mesa, California • San Diego, California + 10 more

Conditions: Hepatitis C Virus
Interventions: Placebo, Daclatasvir, Pegylated interferon alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Tulsa, Oklahoma + 1 more

Conditions: End Stage Renal Disease, Hepatitis C
Interventions: Glecaprevir/pibrentasvir; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis B
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C Virus (HCV)
Interventions: Pegylated Interferon Lambda, Pegylated Interferon Alfa-2a, Ribavirin; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: San Diego, California • Rochester, New York • Houston, Texas

Search by objective public record fields.

Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs

A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects

Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)

Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial

Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis

Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1

Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection

Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin

A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

A Long-term Observational Study in Participants Who Have Received PBGENE-HBV

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors

Hepatitis B Reactivation During Treatment With Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection

Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C